6 terminated, 5 completed, 4 unknown, 3 not yet recruiting. 20 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Terminated 6, Completed 5, Unknown 4, Not yet recruiting 3, Recruiting 1, Withdrawn 1 |
| Phase 1 | 2 | Not yet recruiting 1, Unknown 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow CHOP: new trials by email Literature Review of CHOP trials Research Report on CHOP
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| New Genotype-guided Treatment in Newly Diagnosed PTCL Azacitidine plus Selinexor with CHOP, Decitabine plus Selinexor with CHOP, Zeprumetostat plus chidamide with CHOP - Peripheral T-cell Lymphoma (PTCL) | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 108 | 2026-07-01 | 2026-07-16 |
| Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A Obinutuzumab, CHOP, Bendamustine - Follicular Lymphoma Grade 3A | Phase 2 | Not yet recruiting | Sun Yat-sen University | 133 | 2025-05-01 | 2025-05-08 |
| A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma Linperlisib - Peripheral T Cell Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Shanghai YingLi Pharmaceutical Co. Ltd. | 606 | 2024-09-10 | 2024-08-12 |
| Parsaclisib in Combination With CHOP in Participants With Previously Untreated PTCL Parsaclisib, CHOP - PI3Kδ Inhibitor, Parsaclisib | Phase 1 / Phase 2 | Unknown | Fudan University | 30 | 2022-03-01 | 2022-02-14 |
| Targeted Drug Combined With CHOP in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma CHOP, CHOP+X - Peripheral T-cell Lymphoma | Phase 2 | Unknown | Ruijin Hospital | 96 | 2020-07-29 | 2023-06-13 |
| Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma DA-EPOCH, Rituximab, CHOP - Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 132 | 2019-08-05 | 2026-10-26 |
| Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients Obinutuzumab, Ibrutinib, CHOP - Richter Syndrome | Phase 2 | Terminated | Northwell Health | 3 | 2017-06-19 | 2023-06-01 |
| Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. Obinutuzumab, Ibrutinib, CHOP - Lymphoma, B-Cell | Phase 2 | Terminated | Fondazione Italiana Linfomi - ETS | 1 | 2016-09-01 | 2017-03-20 |
| Duvelisib With Rituximab vs R-CHOP in Subjects With Relapsed/Refractory Follicular Lymphoma (FRESCO) Duvelisib, Rituximab, R-CHOP - Lymphoma | Phase 2 | Withdrawn | SecuraBio | 2015-12-01 | 2021-03-17 | |
| Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL CHOP, fractionated ICED - Peripheral T-cell Lymphoma | Phase 2 | Unknown | Samsung Medical Center | 134 | 2015-09-23 | 2020-10-22 |
| Bevacizumab + CHOP-Rituximab in Untreated Mantle Cell Lymphoma Bevacizumab, Rituximab, CHOP - Untreated Mantle Cell Lymphoma | Phase 2 | Completed | Weill Medical College of Cornell University | 11 | 2007-11-01 | 2017-10-20 |
| Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients Ofatumumab, Cyclophosphamide, Doxorubicin - Lymphoma, Follicular | Phase 2 | Completed | GlaxoSmithKline | 59 | 2007-06-01 | 2014-07-11 |
| CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma CHOP + CD4, CHOP - T-cell Lymphoma | Phase 2 | Terminated | Emergent BioSolutions | 5 | 2007-05-01 | 2026-10-07 |
| CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma GM-CSF, CHOP, Rituximab - Lymphoma, Non-Hodgkin, Lymphoma, B-Cell | Phase 2 | Terminated | Massachusetts General Hospital | 3 | 2006-12-01 | 2018-01-18 |
| Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma Immunochemotherapy, High-dose BEAM plus autologous SCT, HLA-identical allogenic SCT - Mantle-Cell Lymphoma | Phase 2 | Unknown | Heidelberg University | 20 | 2004-07-01 | 2009-07-27 |
| A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma Denileukin diftitox, Cyclophosphamide, Doxorubicin - Lymphoma, T-Cell, Peripheral | Phase 2 | Completed | Eisai Inc. | 49 | 2004-03-14 | 2020-03-18 |
| Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD) Rituximab, CHOP - Post-transplantation Lymphoproliferative Disorder | Phase 2 | Terminated | Charite University, Berlin, Germany | 70 | 2002-12-01 | 2011-10-25 |
| Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma Rituximab, CHOP, CVP - Non-Hodgkins Lymphoma | Phase 2 | Completed | SCRI Development Innovations, LLC | 40 | 2002-04-01 | 2010-12-30 |
| Phase II Study of Combined Modality Treatment in Primary Testicular Non-Hodgkin's Lymphoma rituximab, CHOP, intrathecal methotrexate - Lymphoma, B Cell | Phase 2 | Completed | International Extranodal Lymphoma Study Group (IELSG) | 64 | 2000-11-01 | 2009-07-22 |
| Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma rituximab, CHOP - AIDS Related Lymphoma | Phase 2 | Terminated | French National Agency for Research on AIDS and Viral Hepatitis | 60 | 1999-01-01 | 2005-08-17 |
Lymphoma, T-Cell, Peripheral (5) · Lymphoma, Non-Hodgkin (4) · Lymphoma, B-Cell (3) · Lymphoma, Large B-Cell, Diffuse (2) · Leukemia (1) · Lymphoma (1) · Lymphoma, AIDS-Related (1) · Lymphoma, Follicular (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell (1)
Ruijin Hospital (2) · Charite University, Berlin, Germany (1) · Eisai Inc. (1) · Emergent BioSolutions (1) · Fondazione Italiana Linfomi - ETS (1) · French National Agency for Research on AIDS and Viral Hepatitis (1) · Fudan University (1) · GlaxoSmithKline (1) · Heidelberg University (1) · International Extranodal Lymphoma Study Group (IELSG) (1) · Massachusetts General Hospital (1) · National Cancer Institute (NCI) (1) · Northwell Health (1) · SCRI Development Innovations, LLC (1) · Samsung Medical Center (1)
United States (7) · China (3) · France (2) · Germany (2) · Australia (1) · Italy (1) · South Korea (1) · Sweden (1) · Switzerland (1)
Andreas Sarris, MD (1) · Anthony D. Ho, Ph.D., Prof. (1) · Christopher J Melani, M.D. (1) · Dominique Costagliola (1) · Emanuele Zucca, MD (1) · Ephraim P Hochberg, MD (1) · Francois Boue, MD (1) · Hagop Youssoufian, MD (1) · Jacqueline Barrientos, MD (1) · John D. Hainsworth, MD (1) · John P Leonard, MD (1) · Junning Cao (1) · Mary Gospodarowicz, MD (1) · Maurizio Martelli, MD (1)
PMID 19525191, PMID 22173060, PMID 23278639, PMID 27992268, PMID 39175480, PMID 40802906
2015 (2)